BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Palasik BN, Wang H. Tofacitinib, the First Oral Janus Kinase Inhibitor Approved for Adult Ulcerative Colitis. J Pharm Pract 2020;:897190020953019. [PMID: 32873116 DOI: 10.1177/0897190020953019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Lee JS, Kim HS, Jung YS, Choi HG, Kim SH. Pharmacokinetic Drug Interaction between Tofacitinib and Voriconazole in Rats. Pharmaceutics 2021;13:740. [PMID: 34069798 DOI: 10.3390/pharmaceutics13050740] [Reference Citation Analysis]
2 Yang J, Xie X. Tofacitinib protects intestinal epithelial cells against oxygen-glucose deprivation/reoxygenation injury by inhibiting the JAK/STAT3 signaling pathway. Exp Ther Med 2021;22:1108. [PMID: 34504562 DOI: 10.3892/etm.2021.10542] [Reference Citation Analysis]